MedKoo Cat#: 413278 | Name: Inamrinone Free Base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Inamrinone Free Base is a positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.

Chemical Structure

Inamrinone Free Base
Inamrinone Free Base
CAS#60719-84-8 (free base)

Theoretical Analysis

MedKoo Cat#: 413278

Name: Inamrinone Free Base

CAS#: 60719-84-8 (free base)

Chemical Formula: C10H9N3O

Exact Mass: 187.0746

Molecular Weight: 187.20

Elemental Analysis: C, 64.16; H, 4.85; N, 22.45; O, 8.55

Price and Availability

Size Price Availability Quantity
250mg USD 250.00 2 Weeks
1g USD 550.00 2 Weeks
5g USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Inamrinone Free Base; CCRIS3794; CCRIS-3794; CCRIS 3794; Amrinone; Win 40680; Win-40680; Win40680; Inocor; Wincoram; Cordemcura
IUPAC/Chemical Name
5-amino-[3,4'-bipyridin]-6(1H)-one
InChi Key
RNLQIBCLLYYYFJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)
SMILES Code
O=C1C(N)=CC(C2=CC=NC=C2)=CN1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
Soluble in DMSO 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 187.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shepherd G. Treatment of poisoning caused by beta-adrenergic and calcium- channel blockers. Am J Health Syst Pharm. 2006 Oct 1;63(19):1828-35. doi: 10.2146/ajhp060041. Erratum in: Am J Health Syst Pharm. 2008 Sep 1;65(17):1592. PMID: 16990629. 2: Levy JH, Bailey JM. Amrinone: pharmacokinetics and pharmacodynamics. J Cardiothorac Anesth. 1989 Dec;3(6 Suppl 2):10-4. doi: 10.1016/0888-6296(89)90054-9. PMID: 2521045. 3: Kullberg MP, Freeman GB, Biddlecome C, Alousi AA, Edelson J. Amrinone metabolism. Clin Pharmacol Ther. 1981 Mar;29(3):394-401. doi: 10.1038/clpt.1981.54. PMID: 7471610. 4: Honerjäger P. Pharmacology of bipyridine phosphodiesterase III inhibitors. Am Heart J. 1991 Jun;121(6 Pt 2):1939-44. doi: 10.1016/0002-8703(91)90828-6. PMID: 1852089. 5: Carpati CM, Astiz ME, Rackow EC. Mechanisms and management of myocardial dysfunction in septic shock. Crit Care Med. 1999 Feb;27(2):231-2. doi: 10.1097/00003246-199902000-00002. PMID: 10075029. 6: Alonso Francia C, Calvo Cebollero I, Diarte de Miguel JA, Gomollón García JP, Placer Peralta LJ. Opciones terapéuticas en el shock cardiogénico [Therapeutic options in cardiogenic shock]. Rev Esp Cardiol. 1995 Sep;48(9):573-80. Spanish. PMID: 7569257. 7: Löllgen H, Drexler H. Use of inotropes in the critical care setting. Crit Care Med. 1990 Jan;18(1 Pt 2):S56-60. PMID: 2136722. 8: Ross MP, Allen-Webb EM, Pappas JB, McGough EC. Amrinone-associated thrombocytopenia: pharmacokinetic analysis. Clin Pharmacol Ther. 1993 Jun;53(6):661-7. doi: 10.1038/clpt.1993.87. PMID: 8513658. 9: Levy JH, Bailey JM. Perioperative experience with amrinone. Eur J Anaesthesiol Suppl. 1992;5:15-9. PMID: 1600963. 10: Butterworth J. Selecting an inotrope for the cardiac surgery patient. J Cardiothorac Vasc Anesth. 1993 Aug;7(4 Suppl 2):26-32. doi: 10.1016/1053-0770(93)90094-2. PMID: 8103680.